Composition for treatment of insulin resistance syndromes

Details Composition for treatment of insulin resistance syndromes Composition for treatment of insulin resistance syndromes

A - Human Necessities

61

K

A61K 33/06 (2006.01) A61K 33/24 (2006.01)

Patent

CA 2142956

The use of the compound magnesium vanadate in the manufacture of a pharmaceutical composition for treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus. Daily dosage ranges are preferably from about 2 to about 60 mg of magnesium vanadate per kg of patient body weight. The pharmaceutical compositions include at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.

Affiliated with

Also associated with

Rating

Composition for treatment of insulin resistance syndromes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition for treatment of insulin resistance syndromes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treatment of insulin resistance syndromes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1620437